DF/HCC Kidney Cancer SPORE

DF/HCC 肾癌孢子

• 批准号: 7910615
• 负责人: Michael Benjamin Atkins
• 金额: $ 230万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-18 至 2014-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7910615
• 关键词: DF; HCC; Kidney; Cancer; SPORE

This application represents the renewal of the Specialized Program of Research Excellence in Kidney Cancer originating from the Kidney Cancer Program of the Dana-Farber Harvard Cancer Center (DF/HCC) and the Beth Israel Deaconess Medical Center. The DF/HCC Kidney Cancer SPORE includes investigators from all the Harvard affiliated hospitals - the Beth Israel Deaconess Medical Center, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, the Brigham and Women's Hospital, and the Children's Hospital Medical Center, as well as the Harvard School of Public Health. Five major projects are supported through this application including: 1) Clinical Correlations of WTX Inactivation in Wilms Tumor; 2) Validation of RCC biomarkers for early disease detection and response to targeted therapy; 3) Acquired Resistance to VEGF Receptor Blockade: Underlying Mechanism and Therapeutic Options; 4), Targeting the PI3-Kinase/Akt Pathway in RCC: Mechanism of Action and Opportunities for Rational Combination Therapy; and 5) Adoptive Immunotherapy for Renal Carcinoma Using Dendritic Cell/tumor Fusions. These projects are integrated by three cores. These are: 1) Administration, Evaluation and Planning; 2) Biostatistics; and 3) Tissue Acquisition, Pathology and Clinical Data, This SPORE application outlines a Development Research Program which includes a plan for selection and review of new projects and examples of 4 recently funded and 3 projects that could be considered for future support. We also include a Career Development Program which outlines a mechanism for the identification, support, and review of talented young investigators in renal cancer. The overall goal of the DF/HCC Kidney Cancer SPORE is the translation of biological and technological advances into clinically meaningful advances for patients with kidney cancer.

该申请代表了源自丹娜-法伯哈佛癌症中心（DF/HCC）和贝斯以色列女执事医疗中心肾癌项目的肾癌卓越研究专业项目的更新。DF/HCC肾癌孢子包括来自所有哈佛附属医院的研究人员-贝斯以色列女执事医疗中心，丹娜法伯癌症研究所，马萨诸塞州总医院，布莱根妇女医院，儿童医院医疗中心，以及哈佛大学公共卫生学院。通过该申请支持5个主要项目，包括：1)Wilms肿瘤WTX失活的临床相关性；2)验证RCC生物标志物对疾病早期检测和靶向治疗的反应；3)对VEGF受体阻断的获得性耐药：潜在机制和治疗选择；4)、靶向RCC中pi3 -激酶/Akt通路：作用机制及合理联合治疗的机会；5)利用树突状细胞/肿瘤融合物对肾癌进行过继免疫治疗。这些项目由三个核心组成。它们是：1)行政、评价和规划；2)生物统计学;该SPORE申请概述了一个发展研究计划，其中包括新项目的选择和审查计划，以及最近资助的4个项目和可能考虑未来支持的3个项目的例子。我们还包括一个职业发展计划，概述了识别、支持和审查肾癌领域有才华的年轻研究者的机制。DF/HCC肾癌孢子的总体目标是将生物学和技术进步转化为对肾癌患者有临床意义的进展。